Use of the next-generation functional diagnostics in cancer precision medicine

One of the precision medicine concepts is the allocating a specific drug to particular patient based on genetic profile and ethnicity. In cancer, there is a growing tendency to make precision medicine synonymous with genomics. In current methods, functional testing is used to remove the limitations of old therapies based on the phenotype-genotype relationship, including live tumor cells exposure to adjuvant therapy and following assessment of cells before and after treatment. One application of tumor tissue sample and chemical agent’s effects on that is a target therapy of HER2 positives treated with adjuvant therapy. In this treatment, as well as switching off the HER2 pathway, other pathway is to become switched with on and resulted side effect is metastasis.By surveying tumor tissues and their expression profiling, these pathways can be found, while applying the adjuvant and Herceptin, an approviate silencer can be used for switching on side effects of adjuvant and reduction of metastasis. Currently, there are several next generation functional diagnostic technologies, including novel methods for tumor manipulation such as conditional reprogramming (CR), circulating tumor cells (CTC) and also insitu methods based on tools. The aim of these new technologies is to integrate functional testing with next generation sequencing and immunoprofiling to precisely match combination therapies for a specific cancer patient.

کلیدواژه ها:

Precision medicine ، Next generation sequencing ، Adjuvant therapy ، HER2